Literature DB >> 11882513

Acute hyperglycemia alters the ability of the normal beta-cell to sense and respond to glucose.

Jürgen Meyer1, Jeppe Sturis, Martin Katschinski, Rudolf Arnold, Burkhard Göke, Maria M Byrne.   

Abstract

Impaired glucose tolerance (IGT) and non-insulin-dependent diabetes mellitus (NIDDM) are associated with an impaired ability of the beta-cell to sense and respond to small changes in plasma glucose. The aim of this study was to establish whether acute hyperglycemia per se plays a role in inducing this defect in beta-cell response. Seven healthy volunteers with no family history of NIDDM were studied on two occasions during a 12-h oscillatory glucose infusion with a periodicity of 144 min. Once, low-dose glucose was infused at a mean rate of 6 mg x kg(-1) x min(-1) and amplitude 33% above and below the mean rate, and, once, high-dose glucose was infused at 12 mg x kg(-1) x min(-1) and amplitude 16% above and below the mean rate. Mean glucose levels were significantly higher during the high-dose compared with the low-dose glucose infusion [9.5 +/- 0.8 vs. 6.8 +/- 0.2 mM (P < 0.01)], resulting in increased mean insulin secretion rates [ISRs; 469.1 +/- 43.8 vs. 268.4 +/- 29 pmol/min (P < 0.001)] and mean insulin levels [213.6 +/- 46 vs. 67.9 +/- 10.9 pmol/l (P < 0.008)]. Spectral analysis evaluates the regularity of oscillations in glucose, insulin secretion, and insulin at a predetermined frequency. Spectral power for glucose, ISR, and insulin was reduced during the high-dose glucose infusion [11.8 +/- 1.4 to 7.0 +/- 1.6 (P < 0.02), 7.6 +/- 1.5 to 3.2 +/- 0.5 (P < 0.04), and 10.5 +/- 1.6 to 4.6 +/- 0.7 (P < 0.01), respectively]. In conclusion, short-term infusion of high-dose glucose to obtain glucose levels similar to those previously seen in IGT subjects results in reduced spectral power for glucose, ISR, and insulin. The reduction in spectral power previously observed for ISR in IGT or NIDDM subjects may be due partly to hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882513     DOI: 10.1152/ajpendo.00427.2001

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  7 in total

1.  A higher-carbohydrate, lower-fat diet reduces fasting glucose concentration and improves β-cell function in individuals with impaired fasting glucose.

Authors:  Barbara A Gower; Laura Lee Goree; Paula C Chandler-Laney; Amy C Ellis; Krista Casazza; Wesley M Granger
Journal:  Metabolism       Date:  2011-09-23       Impact factor: 8.694

2.  A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes.

Authors:  Barbara A Gower; Amy M Goss
Journal:  J Nutr       Date:  2014-12-03       Impact factor: 4.798

3.  Dapagliflozin lowers plasma glucose concentration and improves β-cell function.

Authors:  Aurora Merovci; Andrea Mari; Carolina Solis-Herrera; Juan Xiong; Giuseppe Daniele; Alberto Chavez-Velazquez; Devjit Tripathy; Scheherezada Urban McCarthy; Muhammad Abdul-Ghani; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2015-02-24       Impact factor: 5.958

4.  Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS.

Authors:  Barbara A Gower; Paula C Chandler-Laney; Fernando Ovalle; Laura Lee Goree; Ricardo Azziz; Renee A Desmond; Wesley M Granger; Amy M Goss; G Wright Bates
Journal:  Clin Endocrinol (Oxf)       Date:  2013-05-20       Impact factor: 3.478

5.  The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance.

Authors:  Muhammad A Abdul-Ghani; Masafumi Matsuda; Rucha Jani; Christopher P Jenkinson; Dawn K Coletta; Kohei Kaku; Ralph A DeFronzo
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

Review 6.  Molecular basis for the integration of inositol phosphate signaling pathways via human ITPK1.

Authors:  Stephen B Shears
Journal:  Adv Enzyme Regul       Date:  2009-01-03

7.  Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance.

Authors:  Mustafa Kanat; Andrea Mari; Luke Norton; Diedre Winnier; Ralph A DeFronzo; Chris Jenkinson; Muhammad A Abdul-Ghani
Journal:  Diabetes       Date:  2012-02       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.